Detailed information on CD19 CAR T-cell therapy and related events
| Parameters . | N = 3350 (%) . |
|---|---|
| LD chemotherapy, n (%) | |
| Fludarabine-based regimens∗ | 3224 (96.2) |
| Bendamustine-based regimens† | 103 (3.1) |
| Single-agent cyclophosphamide | 8 (0.2) |
| Others or not specified | 15 (0.4) |
| Median time from LD chemotherapy to CAR T-cell infusion (IQR), d | 5 (5-5) |
| CAR T-cell product | |
| Axi-cel | 2804 (83.7) |
| Tisa-cel | 546 (16.3) |
| Median total CAR T-cell dose (IQR), ×108 cells | 2 (1.4-7) |
| Median time from CAR T-cell infusion to CRS onset (range), d | 4 (2-6) |
| Severity of CRS,‡ n (%) | |
| Grade 0 | 777 (23.2) |
| Grade 1-2 | 2305 (68.8) |
| Grade ≥3 | 268 (8.0) |
| Median time from CAR T-cell infusion to ICANS onset (range), d | 7 (5-9) |
| Severity of ICANS,‡ n (%) | |
| Grade 0 | 2207 (65.9) |
| Grade 1-2 | 562 (16.8) |
| Grade ≥3 | 581 (17.3) |
| Receipt of tocilizumab, n (%) | |
| Yes | 1816 (54.2) |
| No | 1489 (44.4) |
| Missing | 45 (1.3) |
| Receipt of systemic corticosteroid, n (%) | |
| Yes | 1450 (43.3) |
| No | 1831 (54.7) |
| Missing | 69 (2.1) |
| Median time to neutrophil recovery (range), d | 10 (6-13) |
| Delayed neutrophil recovery,§ n (%) | 388 (11.6) |
| Parameters . | N = 3350 (%) . |
|---|---|
| LD chemotherapy, n (%) | |
| Fludarabine-based regimens∗ | 3224 (96.2) |
| Bendamustine-based regimens† | 103 (3.1) |
| Single-agent cyclophosphamide | 8 (0.2) |
| Others or not specified | 15 (0.4) |
| Median time from LD chemotherapy to CAR T-cell infusion (IQR), d | 5 (5-5) |
| CAR T-cell product | |
| Axi-cel | 2804 (83.7) |
| Tisa-cel | 546 (16.3) |
| Median total CAR T-cell dose (IQR), ×108 cells | 2 (1.4-7) |
| Median time from CAR T-cell infusion to CRS onset (range), d | 4 (2-6) |
| Severity of CRS,‡ n (%) | |
| Grade 0 | 777 (23.2) |
| Grade 1-2 | 2305 (68.8) |
| Grade ≥3 | 268 (8.0) |
| Median time from CAR T-cell infusion to ICANS onset (range), d | 7 (5-9) |
| Severity of ICANS,‡ n (%) | |
| Grade 0 | 2207 (65.9) |
| Grade 1-2 | 562 (16.8) |
| Grade ≥3 | 581 (17.3) |
| Receipt of tocilizumab, n (%) | |
| Yes | 1816 (54.2) |
| No | 1489 (44.4) |
| Missing | 45 (1.3) |
| Receipt of systemic corticosteroid, n (%) | |
| Yes | 1450 (43.3) |
| No | 1831 (54.7) |
| Missing | 69 (2.1) |
| Median time to neutrophil recovery (range), d | 10 (6-13) |
| Delayed neutrophil recovery,§ n (%) | 388 (11.6) |
LD, lymphodepletion.
Fludarabine-based regimens: fludarabine + cyclophosphamide, fludarabine + carboplatin, fludarabine + cytarabine, fludarabine + cytarabine + cyclophosphamide, fludarabine + cyclophosphamide + others, single-agent fludarabine.
Bendamustine-based regimens: bendamustine, bendamustine + cytarabine, bendamustine + cyclophosphamide.
Severity grading according to the American Society of Transplant and Cellular Therapy Consensus Criteria.
No neutrophil recovery after 30 days of CAR T-cell infusion.